Plasma neurofilament light chain (NfL) is a marker of neuronal damage in different neurological disorders and might predict disease progression in dementia with Lewy bodies (DLB). The study enrolled 45 controls and 44 DLB patients (including 17 prodromal cases) who underwent an extensive assessment at baseline and at 2 years follow-up. At baseline, plasma NfL levels were higher in both probable DLB and prodromal cases compared to controls. Plasma NfL emerged as the best predictor of cognitive decline compared to age, sex, and baseline severity variables. The study supports the role of plasma NfL as a useful prognostic biomarker from the early stages of DLB.
McKeithIG, FermanTJ, ThomasAJ, BlancF, BoeveBF, FujishiroH, KantarciK, MuscioC, O’BrienJT, PostumaRB, AarslandD, BallardC, BonanniL, DonaghyP, EmreM, GalvinJE, GalaskoD, GoldmanJG, GompertsSN, HonigLS, IkedaM, LeverenzJB, LewisSJG, MarderKS, MasellisM, SalmonDP, TaylorJP, TsuangDW, WalkerZ, TiraboschiP, prodromal DLB Diagnostic Study Group (2020) Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology94, 743–755.
4.
PilottoA, RomagnoloA, TuazonJA, VizcarraJA, MarsiliL, ZibettiM, RossoM, Rodriguez-PorcelF, BorroniB, RizzettiMC, RossiC, Vizcarra-EscobarD, MolanoJR, LopianoL, CeravoloR, MasellisM, EspayAJ, PadovaniA, MerolaA (2019) Orthostatic hypotension and REM sleep behaviour disorder: Impact on clinical outcomes in α-synucleinopathies. J Neurol Neurosurg Psychiatry90, 1257–1263.
5.
MuellerC, BallardC, CorbettA, AarslandD (2017) The prognosis of dementia with Lewy bodies. Lancet Neurol16, 390–398.
6.
GiilLM, AarslandD (2020) Greater variability in cognitive decline in Lewy body dementia compared to Alzheimer’s disease. J Alzheimers Dis73, 1321–1330.
7.
AshtonN, JanelidzeS, Al KhleifatA, LeuzyA, Van Der EndeE, KarikariT, BenedetA, PascoalT, LleóA, GalimbertiD, BonanniL, PilottoA, PadovaniA, LyckeJ, NovakovaL, AxelssonM, VelayudhanL, RabinoviciG, MillerB, ParianteC, ResnickS, SchöllM, Fernandez-EulateG (2021) Diagnostic value of plasma neurofilament light: A multicentre validation study. Nat Commun12, 3400.
LinCH, LiCH, YangKC, LinFJ, WuCC, ChiehJJ, ChiuMJ (2019) Blood NfL: A biomarker for disease severity and progression in Parkinson disease. Neurology93, e1104–e1111.
11.
BäckströmD, LinderJ, Jakobson MoS, RiklundK, ZetterbergH, BlennowK, ForsgrenL, LenfeldtN (2020) NfL as a biomarker for neurodegeneration and survival in Parkinson disease. Neurology95, e827–e838.
12.
MoscosoA, GrotheMJ, AshtonNJ, KarikariTK, Lantero RodríguezJ, SnellmanA, Suárez-CalvetM, BlennowK, ZetterbergH, SchöllM (2021) Longitudinal associations of blood phosphorylated Tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease. JAMA Neurol78, 396–406.
13.
PilottoA, Cola diFS, PremiE, GrassoR, TurroneR, GipponiS, ScalviniA, CottiniE, PagheraB, GaribottoV, RizzettiMC, BonanniL, BorroniB, MorbelliS, NobiliF, GuerraUP, PeraniD, PadovaniA (2019) Extrastriatal dopaminergic and serotonergic pathways in Parkinson’s disease and in dementia with Lewy bodies: A 123I-FP-CIT SPECT study. Eur J Nucl Med Mol Imaging46, 1642–1651.
14.
TomlinsonCL, StoweR, PatelS, RickC, GrayR, ClarkeCE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord25, 2649–2653.
15.
GoetzCG, TilleyBC, ShaftmanSR, StebbinsGT, FahnS, Martinez-MartinP, PoeweW, SampaioC, SternMB, DodelR, DuboisB, HollowayR, JankovicJ, KulisevskyJ, LangAE, LeesA, LeurgansS, LeWittPA, NyenhuisD, OlanowCW, RascolO, SchragA, TeresiJA, van HiltenJJ, LaPelleN, Movement Disorder Society UPDRS Revision Task Force (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord23, 2129–2170.
16.
CummingsJL (1997) The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology48 (5 Suppl 6), S10–S16.
DisantoG, BarroC, BenkertP, NaegelinY, SchädelinS, GiardielloA, ZeccaC, BlennowK, ZetterbergH, LeppertD, KapposL, GobbiC, KuhleJ (2017) Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol81, 857–870.
19.
HodgeVJ, HodgeVJ, AustinJ (2004) A survey of outlier detection methodologies. Artif Intell Rev22, 2004.
20.
BaciogluM, MaiaLF, PreischeO, SchelleJ, ApelA, KaeserSA, SchweighauserM, EningerT, LambertM, PilottoA, ShimshekDR, NeumannU, KahlePJ, StaufenbielM, NeumannM, MaetzlerW, KuhleJ, JuckerM (2016) Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron91, 56–66.
21.
DelabyC, AlcoleaD, Carmona-IraguiM, Illán-GalaI, Morenas-RodríguezE, BarroetaI, AltunaM, EstellésT, Santos-SantosM, Turon-SansJ, MuñozL, Ribosa-NoguéR, Sala-MataveraI, Sánchez-SaudinosB, SubiranaA, VidelaL, BenejamB, SirisiS, LehmannS, BelbinO, ClarimonJ, BlesaR, PagonabarragaJ, Rojas-GarciaR, ForteaJ, LleóA (2020) Differential levels of neurofilament light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders. Sci Rep10, 9161.
22.
BonanniL, PerfettiB, BifolchettiS, TaylorJ-P, FranciottiR, ParnettiL, ThomasA, OnofrjM (2015) Quantitative electroencephalogram utility in predicting conversion of mild cognitive impairment to dementia with Lewy bodies. Neurobiol Aging36, 434–445.
23.
van der ZandeJJ, GouwAA, van SteenovenI, van de BeekM, ScheltensP, StamCJ, LemstraAW (2020) Diagnostic and prognostic value of EEG in prodromal dementia with Lewy bodies. Neurology95, e662–e670.
24.
NedelskaZ, SchwarzCG, LesnickTG, BoeveBF, PrzybelskiSA, LoweVJ, KremersWK, GunterJL, SenjemML, Graff-RadfordJ, FermanTJ, FieldsJA, KnopmanDS, PetersenRC, JackCR, KantarciK (2019) Association of longitudinal β-amyloid accumulation determined by positron emission tomography with clinical and cognitive decline in adults with probable Lewy body dementia. JAMA Netw Open2, e1916439.
25.
OlssonB, PorteliusE, CullenNC, SandeliusÅ, ZetterbergH, AndreassonU, HöglundK, IrwinDJ, GrossmanM, WeintraubD, Chen-PlotkinA, WolkD, McCluskeyL, ElmanL, ShawLM, ToledoJB, McBrideJ, Hernandez-ConP, LeeVMY, TrojanowskiJQ, BlennowK (2019) Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders. JAMA Neurol76, 318–325.
26.
Abu-RumeilehS, CapellariS, Stanzani-MaseratiM, PolischiB, MartinelliP, CaroppoP, LadoganaA, ParchiP (2018) The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. Alzheimers Res Ther10, 3.
